Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 33Lymphoma, Mantle-Cell 24Burkitt Lymphoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 12Lymphoma, Non-Hodgkin 11Hodgkin Disease 8Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Biphenotypic, Acute 6Leukemia, Myelomonocytic, Chronic 5Leukemia, Myeloid, Accelerated Phase 5Waldenstrom Macroglobulinemia 4Lymphoma, T-Cell 4Lymphoma 4Blast Crisis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic-Phase 3Hematologic Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Hairy Cell 2Composite Lymphoma 2Anemia, Refractory, with Excess of Blasts 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1

Interventions

Peripheral Blood Stem Cell Transplantation 26Rituximab 20Cyclophosphamide 18fludarabine phosphate 17Mycophenolic Acid 16Tacrolimus 14Cyclosporine 14Whole-Body Irradiation 12Filgrastim 11Therapeutics 10Psychiatric Rehabilitation 10Flow Cytometry 10Etoposide 10Radiotherapy 8Polymerase Chain Reaction 8Methotrexate 8Busulfan 8Methylprednisolone 7Antilymphocyte Serum 7Cladribine 6immunotoxin HA22 5Lenalidomide 5obinutuzumab 4Vorinostat 4Vemurafenib 4Ondansetron 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × CT-P10 × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT00412594 2025-12-22

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
150 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡